Fig. 7From: Talniflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment in pancreatic cancerGraphical summary of the study main results. a) GCNT3 and Mucin expression increase throughout the IPMN from Low-grade IPMN to High-grade IPMN and PDAC. b O-glycosilated Mucins shield the tumor cells from T cells improving immune escape. c Talniflumate abrogates GCNT3 activity and impairs teh enzyme expression together with MUC1 and MUC5AC favoring T cell recognition and activationBack to article page